Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mundipharma International Corp. Ltd.

www.mundipharma.co.uk

Latest From Mundipharma International Corp. Ltd.

Pipeline Watch: LentiGlobin, BMS-986205 Phase III Studies Initiated

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

What's Behind The Success Of Korean Biosimilars?

Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.

South Korea Biosimilars

New Drugs Shine But Biosimilars Blunt Roche Revenue Rise

MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.

Biosimilars Sales & Earnings

Pharma Q3 Results Preview: J&J, Roche Set The Scene

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.

Sales & Earnings Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mundipharma International Holdings Ltd.
  • Mundipharma International Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Mundipharma International Corp. Ltd.
  • Senior Management
  • Paul Medeiros, SVP, Corp. & Bus. Dev.
    Antony Mattessich, Managing Dir.
  • Contact Info
  • Mundipharma International Corp. Ltd.
    Phone: (44) 1223 424211
    Cambridge Science Park
    Unit 194
    Milton Rd., CB4 0AB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register